Advertisement

Use of Potentially Nephrotoxic Medications by U.S. Adults with Chronic Kidney Disease: NHANES, 2011–2016

  • Shaheen Kurani
  • Molly Moore Jeffery
  • Bjorg Thorsteinsdottir
  • LaTonya J. Hickson
  • Erin F. Barreto
  • Jordan Haag
  • Rachel Giblon
  • Nilay D. Shah
  • Rozalina G. McCoyEmail author
Original Research

Abstract

Background

People with chronic kidney disease (CKD) are at risk for adverse events and/or CKD progression with use of renally eliminated or nephrotoxic medications.

Objective

To examine the prevalence of potentially inappropriate medication (PIM) use by U.S. adults by CKD stage and self-reported CKD awareness.

Design

Cross-sectional analysis of National Health and Nutrition Examination Surveys, 2011–2016

Participants

Non-pregnant adults with stages 3a (eGFR 45–59 mL/min/1.73 m2), 3b (eGFR 30–44), or 4–5 (eGFR < 30) CKD, stratified as CKD-aware/unaware.

Main Measures

PIMs were identified on the basis of KDIGO guidelines, label information, and literature review. We calculated proportions using any and individual PIMs, assessing for differences over CKD awareness within each CKD stage. Analyses were adjusted for age, sex, race/ethnicity, education, comorbidities, and insurance type.

Key Results

Adjusted proportions of U.S. adults taking any PIM(s) exceeded 50% for all CKD stages and awareness categories, and were highest among CKD-unaware patients with stages 4–5 CKD: 66.6% (95% CI, 55.5–77.8). Proton pump inhibitors, opioids, metformin, sulfonylureas, and non-steroidal anti-inflammatory drugs (NSAIDs) were all used frequently across CKD stages. NSAIDs were used less frequently when CKD-aware by patients with stage 3a CKD (2.2% [95% CI, − 0.3 to 4.7] vs. 10.7% [95% CI, 7.6 to 13.8]) and stages 4–5 CKD (0.8% [95% CI, − 0.9 to 2.5] vs. 16.5% [95% CI, 4.0 to 29.0]). Metformin was used less frequently when CKD-aware by patients with stage 3b CKD (8.1% [95% CI, 0.3–15.9] vs. 26.5% [95% CI, 17.4–35.7]) and stages 4–5 CKD (none vs. 20.8% [95% CI, 1.8–39.8]). The impact of CKD awareness was statistically significant after correction for multiple comparisons only for NSAIDs in stage 3a CKD.

Conclusions

PIMs are frequently used by people with CKD, with some impact of CKD awareness on NSAID and metformin use. This may lead to adverse outcomes or hasten CKD progression, reinforcing the need for improved medication management among people with CKD.

Notes

Authors’ Contributions

Dr. McCoy and Ms. Kurani are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. They affirm that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained. Dr. McCoy designed the study, interpreted the data, and drafted the manuscript. Ms. Kurani and Dr. Jeffery analyzed the data and reviewed/edited the manuscript. Dr. Thorsteinsdottir, Dr. Hickson, Ms. Barreto, Mr. Haag, Ms. Giblon, and Dr. Shah contributed to study design, data interpretation, and reviewed/edited the manuscript.

Funding Information

This work was supported by the Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (K23DK114497 [McCoy] and K23DK109134 [Hickson]), and the National Institute on Aging of the National Institutes of Health (K23AG051679 [Thorsteinsdottir]).

Compliance with Ethical Standards

Conflict of Interest

The authors have no relevant conflicts of interest to declare. In the past 36 months, Dr. McCoy was also supported by the AARP® Quality Measure Innovation Grant through a collaboration with OptumLabs® and the NQF Measure Incubator. Dr. Jeffery has received research support through Mayo Clinic from the National Heart, Lung and Blood Institute (R56HL130496 and R21HL140287), the Agency for Healthcare Research and Quality (R01HS025164), the American Cancer Society (131611-RSGI-17-154-01-CPHPS), the Food and Drug Administration-funded Yale-Mayo CERSI (U01FD 05938), and the National Center for Advancing Translational Sciences (UL1TR 02377; U01TR 02743). In the past 36 months, Dr. Shah has received research support through Mayo Clinic from the Food and Drug Administration to establish Yale-Mayo Clinic Center for Excellence in Regulatory Science and Innovation (CERSI) program (U01FD005938); the Centers of Medicare and Medicaid Innovation under the Transforming Clinical Practice Initiative (TCPI); the Agency for Healthcare Research and Quality (R01HS025164; R01HS025402; R03HS025517); the National Heart, Lung and Blood Institute of the National Institutes of Health (NIH) (R56HL130496; R01HL131535); the National Science Foundation; and the Patient Centered Outcomes Research Institute (PCORI) to develop a Clinical Data Research Network (LHSNet).

Disclaimer

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Supplementary material

11606_2019_5557_MOESM1_ESM.docx (64 kb)
ESM 1 (DOCX 64 kb)

References

  1. 1.
    CDC 2017 Pages. Accessed at US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Division of Diabetes Translation at https://www.cdc.gov/kidneydisease/pdf/kidney_factsheet.pdf on January 10 2019.
  2. 2.
    Tuot DS, Plantinga LC, Hsu C-y, Powe NR. Is awareness of chronic kidney disease associated with evidence-based guideline-concordant outcomes? American journal of nephrology. 2012;35(2):191–7.CrossRefGoogle Scholar
  3. 3.
    Plantinga LC, Tuot DS, Powe NR. Awareness of chronic kidney disease among patients and providers. Advances in chronic kidney disease. 2010;17(3):225–36.CrossRefGoogle Scholar
  4. 4.
    Plantinga LC, Boulware LE, Coresh J, Stevens LA, Miller ER, 3rd, Saran R, et al. Patient awareness of chronic kidney disease: trends and predictors. Arch Intern Med. 2008;168(20):2268–75.CrossRefGoogle Scholar
  5. 5.
    CDC [Website]. 2014;Pages. Accessed at Centers for Disease Control and Prevention at https://nccd.cdc.gov/ckd/data.aspx on February 14 2019.
  6. 6.
    Foreman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey M, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet. 2018;392(10159):2052–90.CrossRefGoogle Scholar
  7. 7.
    Fraser SD, Roderick PJ, May CR, McIntyre N, McIntyre C, Fluck RJ, et al. The burden of comorbidity in people with chronic kidney disease stage 3: a cohort study. BMC Nephrol. 2015;16:193.CrossRefGoogle Scholar
  8. 8.
    Stevens LA, Li S, Wang C, Huang C, Becker BN, Bomback AS, et al. Prevalence of CKD and comorbid illness in elderly patients in the United States: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2010;55(3 Suppl 2):S23–33.CrossRefGoogle Scholar
  9. 9.
    Tonelli M, Wiebe N, Guthrie B, James MT, Quan H, Fortin M, et al. Comorbidity as a driver of adverse outcomes in people with chronic kidney disease. Kidney Int. 2015;88(4):859–66.CrossRefGoogle Scholar
  10. 10.
    Lea-Henry TN, Carland JE, Stocker SL, Sevastos J, Roberts DM. Clinical pharmacokinetics in kidney disease. Fundamental Principles. 2018;13(7):1085–95.Google Scholar
  11. 11.
    Hemmelgarn BR, Manns BJ, Lloyd A, James MT, Klarenbach S, Quinn RR, et al. Relation between kidney function, proteinuria, and adverse outcomes. JAMA. 2010;303(5):423–9.CrossRefGoogle Scholar
  12. 12.
    KDIGO. KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International Supplements. 2013;3(1):1–150.CrossRefGoogle Scholar
  13. 13.
    Adverse drug effects in relation to renal function: Jick H: Am J Med 62: 514–517, 1977. The American Journal of Medicine. 1977;62(4):A97.Google Scholar
  14. 14.
    Brater DC. Drug dosing in patients with impaired renal function. Clin Pharmacol Ther. 2009;86(5):483–9.CrossRefGoogle Scholar
  15. 15.
    Brownlee S, Garber J. Medication overload: America’s other drug problem. In: Institute L, ed. Brookline, MA: Lown Institute; 2017.Google Scholar
  16. 16.
    Whittaker CF, Miklich MA, Patel RS, Fink JC. Medication safety principles and practice in CKD. Clinical Journal of the American Society of Nephrology. 2018;13(11):1738–46.CrossRefGoogle Scholar
  17. 17.
    Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.CrossRefGoogle Scholar
  18. 18.
    Micromedex® (electronic version). Greenwood Village, Colorado, USA: IBM Watson Health; 2019.Google Scholar
  19. 19.
    McCoy AB, Waitman LR, Gadd CS, Danciu I, Smith JP, Lewis JB, et al. A computerized provider order entry intervention for medication safety during acute kidney injury: a quality improvement report. American Journal of Kidney Diseases. 2010;56(5):832–41.CrossRefGoogle Scholar
  20. 20.
    Moffett BS, Goldstein SL. Acute kidney injury and increasing nephrotoxic-medication exposure in noncritically-ill children. Clinical Journal of the American Society of Nephrology. 2011;6(4):856–63.CrossRefGoogle Scholar
  21. 21.
    Ingrasciotta Y, Sultana J, Giorgianni F, Caputi AP, Arcoraci V, Tari DU, et al. The burden of nephrotoxic drug prescriptions in patients with chronic kidney disease: a retrospective population-based study in Southern Italy. PLoS One. 2014;9(2):e89072.CrossRefGoogle Scholar
  22. 22.
    CDC;Pages. Accessed at U.S. Department of Health and Human Services at https://www.cdc.gov/nchs/tutorials/NHANES/NHANESAnalyses/NHANES_Analyses_intro.htm on April 9 2019.
  23. 23.
    Norton EC, Dowd BE, Maciejewski ML. Marginal effects-quantifying the effect of changes in risk factors in logistic regression models. JAMA. 2019.Google Scholar
  24. 24.
    Wasserstein RL, Lazar NA. The ASA’s statement on p-values: context, process, and purpose. The American Statistician. 2016;70(2):129–33.CrossRefGoogle Scholar
  25. 25.
    Holm S. A simple sequentially rejective multiple test procedure. Scandinavian Journal of Statistics. 1979;6(2):65–70.Google Scholar
  26. 26.
    Zhan M, St. Peter WL, Doerfler RM, Woods CM, Blumenthal JB, Diamantidis CJ, et al. Patterns of NSAIDs use and their association with other analgesic use in CKD. Clinical Journal of the American Society of Nephrology. 2017;12(11):1778–86.CrossRefGoogle Scholar
  27. 27.
    Winkelmayer WC, Waikar SS, Mogun H, Solomon DH. Nonselective and cyclooxygenase-2-selective NSAIDs and acute kidney injury. Am J Med. 2008;121(12):1092–8.CrossRefGoogle Scholar
  28. 28.
    Farag A, Garg AX, Li L, Jain AK. Dosing errors in prescribed antibiotics for older persons with CKD: a retrospective time series analysis. Am J Kidney Dis. 2014;63(3):422–8.CrossRefGoogle Scholar
  29. 29.
    Tseng CL, Soroka O, Maney M, Aron DC, Pogach LM. Assessing potential glycemic overtreatment in persons at hypoglycemic risk. JAMA Intern Med. 2014;174(2):259–68.CrossRefGoogle Scholar
  30. 30.
    Yao X, Tangri N, Gersh BJ, Sangaralingham LR, Shah ND, Nath KA, et al. Renal outcomes in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2017;70(21):2621–32.CrossRefGoogle Scholar
  31. 31.
    Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176(2):238–46.CrossRefGoogle Scholar
  32. 32.
    Xie Y, Bowe B, Li T, Xian H, Balasubramanian S, Al-Aly Z. Proton pump inhibitors and risk of incident CKD and progression to ESRD. J Am Soc Nephrol. 2016;27(10):3153–63.CrossRefGoogle Scholar
  33. 33.
    Arora P, Gupta A, Golzy M, Patel N, Carter RL, Jalal K, et al. Proton pump inhibitors are associated with increased risk of development of chronic kidney disease. BMC Nephrol. 2016;17(1):112.CrossRefGoogle Scholar
  34. 34.
    Xie Y, Bowe B, Li T, Xian H, Yan Y, Al-Aly Z. Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury. Kidney Int. 2017;91(6):1482–94.CrossRefGoogle Scholar
  35. 35.
    Rodriguez-Poncelas A, Barcelo MA, Saez M, Coll-de-Tuero G. Duration and dosing of proton pump inhibitors associated with high incidence of chronic kidney disease in population-based cohort. PLoS One. 2018;13(10):e0204231.CrossRefGoogle Scholar
  36. 36.
    Qiu T, Zhou J, Zhang C. Acid-suppressive drugs and risk of kidney disease: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2018.Google Scholar
  37. 37.
    Klatte DCF, Gasparini A, Xu H, de Deco P, Trevisan M, Johansson ALV, et al. Association between proton pump inhibitor use and risk of progression of chronic kidney disease. Gastroenterology. 2017;153(3):702–10.CrossRefGoogle Scholar
  38. 38.
    Davison SN. Clinical pharmacology considerations in pain management in patients with advanced kidney failure. Clinical Journal of the American Society of Nephrology. 2019: https://doi.org/10.2215/CJN.05180418.CrossRefGoogle Scholar
  39. 39.
    Dean M. Opioids in renal failure and dialysis patients. J Pain Symptom Manage. 2004;28(5):497–504.CrossRefGoogle Scholar
  40. 40.
    Afkarian M, Zelnick LR, Hall YN, Heagerty PJ, Tuttle K, Weiss NS, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988–2014. JAMA. 2016;316(6):602–10.CrossRefGoogle Scholar
  41. 41.
    ADA. American Diabetes Association Standards of Medical Care in Diabetes—2019. Section 9. Pharmacologic Approaches to Glycemic Treatment. Diabetes Care. 2019;42(Supplement 1):S90–S102.Google Scholar
  42. 42.
    FDA 2016;Pages. Accessed at U.S. Food and Drug Administration at https://www.fda.gov/Drugs/DrugSafety/ucm493244.htm on February 21 2019.
  43. 43.
    Silbert R, Salcido-Montenegro A, Rodriguez-Gutierrez R, Katabi A, McCoy RG. Hypoglycemia among patients with type 2 diabetes: epidemiology, risk factors, and prevention strategies. Curr Diab Rep. 2018;18(8):53.CrossRefGoogle Scholar
  44. 44.
    Williams AW, Dwyer AC, Eddy AA, Fink JC, Jaber BL, Linas SL, et al. Critical and honest conversations: the evidence behind the “Choosing Wisely” campaign recommendations by the American Society of Nephrology. Clin J Am Soc Nephrol. 2012;7(10):1664–72.CrossRefGoogle Scholar
  45. 45.
    Schneider V, Levesque LE, Zhang B, Hutchinson T, Brophy JM. Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: a population-based, nested case-control analysis. Am J Epidemiol. 2006;164(9):881–9.CrossRefGoogle Scholar

Copyright information

© Society of General Internal Medicine 2019

Authors and Affiliations

  • Shaheen Kurani
    • 1
  • Molly Moore Jeffery
    • 2
  • Bjorg Thorsteinsdottir
    • 3
    • 4
  • LaTonya J. Hickson
    • 3
    • 5
  • Erin F. Barreto
    • 3
    • 6
  • Jordan Haag
    • 6
  • Rachel Giblon
    • 3
  • Nilay D. Shah
    • 2
    • 3
  • Rozalina G. McCoy
    • 2
    • 3
    • 4
    Email author
  1. 1.Mayo Clinic Graduate School of Biomedical SciencesMayo ClinicRochesterUSA
  2. 2.Division of Health Care Policy & Research, Department of Health Sciences ResearchMayo ClinicRochesterUSA
  3. 3.Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care DeliveryMayo ClinicRochesterUSA
  4. 4.Division of Community Internal Medicine, Department of Medicine Mayo ClinicRochesterUSA
  5. 5.Division of Nephrology and Hypertension, Department of MedicineMayo ClinicRochesterUSA
  6. 6.Department of PharmacyMayo ClinicRochesterUSA

Personalised recommendations